Is Glenmark Pharmaceuticals (GLENMARK) overvalued or fairly valued?

MarketChacha shows Glenmark Pharmaceuticals's valuation in context — a forward P/E of about 22.8, a price-to-book of about 6.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Glenmark Pharmaceuticals's revenue?

Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr for FY2026, with net profit of ₹1,362 Cr, per official filings.

What is the share price of Glenmark Pharmaceuticals (GLENMARK)?

Glenmark Pharmaceuticals last traded at ₹2,232.50 (-0.1% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Glenmark Pharmaceuticals

GLENMARK · NSE · Pharma · India

₹2,232.50-0.1%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:38 AM

Snapshot

TickerGLENMARK

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersMumbai, India

Market cap₹63,199 Cr

P/B6.0

Volume1.11L

Websiteglenmarkpharma.com

Filings tracked0

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters49.0%
Institutions27.3%
Public & other23.8%

113 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend2.3% → 8.0%

Margin has expanded by about 5.7 points — the business is getting more profitable.

Growth qualityrev 9% · PAT 66%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,003 Cr

Next fiscal year

Rev ₹18,536 Cr · EPS 98.29

Est. earnings growth +21.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,792.6052-wk range₹2,474.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹63,199 Cr

Day change

-0.1%

Fwd P/E

22.8

P/B

6.0

Div yield

0.22%

Beta

0.26

Revenue (FY2026)

₹16,983 Cr

Net margin

8.0%

Revenue CAGR (3y)

+9.3%

Profit CAGR (3y)

+66.1%

Net profit (FY2026)

₹1,362 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about GLENMARK

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹16,983 Cr	₹1,362 Cr	8.0%
FY2025	₹13,322 Cr	₹1,047 Cr	7.9%
FY2024	₹11,813 Cr	₹-1,502 Cr	-12.7%
FY2023	₹12,990 Cr	₹297 Cr	2.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹3,771 Cr	₹301 Cr	8.0%
2025Q4	₹3,901 Cr	₹403 Cr	10.3%
2025Q3	₹6,047 Cr	₹610 Cr	10.1%
2025Q2	₹3,264 Cr	₹47 Cr	1.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.